Nik Hirani

Nik Hirani

Auto-generated profile, based on publicly available information

Nik Hirani

Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2020 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
NHNikhil Hirani
Nikhil Hirani
AMAlison C. MacKinnon
Alison C. MacKinnon
LNLisa Nicol
Lisa Nicol
PFPaul Ford
Paul Ford
HSHans Schambye
Hans Schambye
TMToby M. Maher
Toby M. Maher
Galectin (Gal)-3 is a profibrotic β-galactoside-binding lectin that plays a key role in the pathogenesis of idiopathic pulmonary fibrosis (IPF) and IPF exacerbations. TD139 is a novel and potent small-molecule inhibitor of Gal-3.A randomised, double-blind, multicentre, placebo-controlled, phase 1/2a study was conducted to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled TD139 in 36 healthy subjects and 24 patients with IPF. Six dose cohorts of six healthy subjects were evaluated (4:2 TD139:placebo ratio) with single doses of TD139 (0.15–50 mg) and three dose cohorts of eight patients with IPF (5:3 TD139:placebo ratio) with once-daily doses of TD139 (0.3–10 mg) for 14 days.Inhaled TD139 was well tolerated with no significant treatment-related side-effects. TD139 was rapidly absorbed, with mean time taken to reach maximum plasma concentration (Cmax) values ranging from 0.6 to 3 h and a plasma half-life (T1/2) of 8 h. The concentration of TD139 in the lung was >567-fold higher than in the blood, with systemic exposure predicting exposure in the target compartment. Gal-3 expression on alveolar macrophages was reduced in the 3 and 10 mg dose groups compared with placebo, with a concentration-dependent inhibition demonstrated. Inhibition of Gal-3 expression in the lung was associated with reductions in plasma biomarkers centrally relevant to IPF pathobiology (platelet-derived growth factor-BB, plasminogen activator inhibitor-1, Gal-3, CCL18 and YKL-40).TD139 is safe and well tolerated in healthy subjects and IPF patients. It was shown to suppress Gal-3 expression on bronchoalveolar lavage macrophages and, in a concerted fashion, decrease plasma biomarkers associated with IPF progression.

27 May 2022 in Nature Immunology
Verified
Journal Article
Open access
PDF file
AMAnanda S. Mirchandani
Ananda S. Mirchandani
SJStephen Jenkins
Stephen Jenkins
CBCalum C. Bain
Calum C. Bain
MSManuel A. Sanchez-Garcia
Manuel A. Sanchez-Garcia
HLHannah Lawson
Hannah Lawson
SWSarah R. Walmsley
Sarah R. Walmsley
Hypoxemia is a defining feature of acute respiratory distress syndrome (ARDS), an often-fatal complication of pulmonary or systemic inflammation, yet the resulting tissue hypoxia, and its impact on immune responses, is often neglected. In the present study, we have shown that ARDS patients were hypoxemic and monocytopenic within the first 48 h of ventilation. Monocytopenia was also observed in mouse models of hypoxic acute lung injury, in which hypoxemia drove the suppression of type I interferon signaling in the bone marrow. This impaired monopoiesis resulted in reduced accumulation of monocyte-derived macrophages and enhanced neutrophil-mediated inflammation in the lung. Administration of colony-stimulating factor 1 in mice with hypoxic lung injury rescued the monocytopenia, altered the phenotype of circulating monocytes, increased monocyte-derived macrophages in the lung and limited injury. Thus, tissue hypoxia altered the dynamics of the immune response to the detriment of the host and interventions to address the aberrant response offer new therapeutic strategies for ARDS.

24 October 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
AAAhsan AKRAM
Ahsan AKRAM
SCSunay V. Chankeshwara
Sunay V. Chankeshwara
ESEmma Scholefield
Emma Scholefield
TATashfeen Aslam
Tashfeen Aslam
NMNeil McDonald
Neil McDonald
KDKevin Dhaliwal
Kevin Dhaliwal
A topically administered fluorescently labeled peptide targeting lipid A permits rapid, real-time visualization of bacteria in the distal human lung.

7 July 2012 in International Journal of Experimental Pathology
Verified
Journal Article
Closed access
PDF file
AAAndreas Alber
Andreas Alber
SHSarah E. M. Howie
Sarah E. M. Howie
WWWilliam A. H. Wallace
William A. H. Wallace
NHNikhil Hirani
Nikhil Hirani

19 November 2021 in Science Immunology
Verified
Journal Article
Open access
JMJack McCowan
Jack McCowan
FFFrédéric Fercoq
Frédéric Fercoq
PKPhoebe M. Kirkwood
Phoebe M. Kirkwood
WTWouter T’jOnck
Wouter T’jOnck
LHLizi M. Hegarty
Lizi M. Hegarty
CBCalum C. Bain
Calum C. Bain
EGR2 controls alveolar macrophage function in health and disease.

Verified
Journal Article
Open access
PDF file
GKGagandeep Kaur
Gagandeep Kaur
KMKrishna Prahlad Maremanda
Krishna Prahlad Maremanda
MCMichael Campos
Michael Campos
HCHitendr Chand
Hitendr Chand
FLFeng Li
Feng Li
Irfan RahmanIrfan Rahman
Irfan Rahman
Chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) are chronic, progressive lung ailments that are characterized by distinct pathologies. Early detection biomarkers and disease mechanisms for these debilitating diseases are lacking. Extracellular vesicles (EVs), including exosomes, are small, lipid-bound vesicles attributed to carry proteins, lipids, and RNA molecules to facilitate cell-to-cell communication under normal and diseased conditions. Exosomal miRNAs have been studied in relation to many diseases. However, there is little to no knowledge regarding the miRNA population of bronchoalveolar lavage fluid (BALF) or the lung-tissue-derived exosomes in COPD and IPF. Here, we determined and compared the miRNA profiles of BALF- and lung-tissue-derived exosomes of healthy non-smokers, smokers, and patients with COPD or IPF in independent cohorts. Results: Exosome characterization using NanoSight particle tracking and TEM demonstrated that the BALF-derived exosomes were ~89.85 nm in size with a yield of ~2.95 × 1010 particles/mL in concentration. Lung-derived exosomes were larger in size (~146.04 nm) with a higher yield of ~2.38 × 1011 particles/mL. NGS results identified three differentially expressed miRNAs in the BALF, while there was one in the lung-derived exosomes from COPD patients as compared to healthy non-smokers. Of these, miR-122-5p was three- or five-fold downregulated among the lung-tissue-derived exosomes of COPD patients as compared to healthy non-smokers and smokers, respectively. Interestingly, there were a large number (55) of differentially expressed miRNAs in the lung-tissue-derived exosomes of IPF patients compared to non-smoking controls. Conclusions: Overall, we identified lung-specific miRNAs associated with chronic lung diseases that can serve as potential biomarkers or therapeutic targets.